Navigation Links
Gene Tests Match Up Lung Tumors, Best Treatment
Date:10/3/2007

DNA indicates whether chemo will work, experts say

WEDNESDAY, Oct. 3 (HealthDay News) -- Identifying a lung tumor's genetic profile may help doctors determine the best chemotherapy for patients, U.S. research suggests.

"We were able to predict which tumors would be most likely to respond to standard first-line therapy and which would respond better to what has traditionally been a second-line therapy, based on gene expression profiling," lead author and oncologist Dr. David Hsu, of Duke University in Durham, N.C., said in a prepared statement.

"This represents a big step in the move toward individualized medicine," he said. "This could also make a huge difference in the treatment of patients with late-stage lung cancer, as most of these patients gain the most benefit from their initial treatment strategy."

The findings are published in the Oct. 1 issue of the Journal of Clinical Oncology.

The researchers determined that there are distinct differences in lung tumors' susceptibility to chemotherapy drugs.

In the first part of the study, Hsu's team found that certain genes expressed in non-small cell lung cancer (NSCLC) tumors known to be sensitive to cisplatin (the most commonly-used agent in the treatment of lung cancer) were not expressed in tumors known to be resistant to cisplatin. They also found that genes expressed in the tumors resistant to cisplatin were expressed in tumors sensitive to it.

In the next phase of the research, the team examined a number of second-line therapies for lung cancer, including pemetrexed, which uses a different mechanism of action to fight NSCLC tumors.

"We found the strongest inverse correlation between tumors that were sensitive to cisplatin and those that were sensitive to pemetrexed," senior author and oncologist Dr. Anil Potti said in a prepared statement. "This suggests that some patients who are not likely to respond to cisplatin should perhaps be treated with pemetrexed first."

The findings have formed the basis of a clinical trial -- the first of its kind in lung cancer -- currently being conducted at Duke University.

"These are not experimental drugs; we know they work. It's just a matter of giving each patient the right one on the first try," Potti said.

More information

The American Medical Association has more about lung cancer.



-- Robert Preidt



SOURCE: Duke University, news release, Sept. 28, 2007


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. IMA wants members not to do sex determination tests during pregnancy
2. Doctors advice early anemia tests
3. Early diagnosis for autism from blood tests may be possible
4. FDA approves Phase 0 trial which tests experimental drugs on humans
5. Genetic tests for cancer
6. Space research leads to needle-free blood tests
7. The Effectiveness Of Screening Tests Questioned
8. Blood Tests Can Help Detect Osteoporosis Early In Life
9. Easier Tests To Detect Tuberculosis
10. Fragile X-Associated Tremor /Ataxia Syndrome Need Guidelines For Diagnostic Tests
11. Skin tests confirms cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... The California State University ... academic faculty engaged in or interested in palliative care education and research. The Symposium, ... held in North County San Diego on Sept. 28 and 29, 2017, on the ...
(Date:2/24/2017)... ... February 24, 2017 , ... Rosica Communications, ... thought leadership , media relations, social media, content marketing and SEO, is ... powered through Act-On, an intuitive marketing automation platform. , Rosica will now offer ...
(Date:2/23/2017)... ... February 23, 2017 , ... The 89th Academy Awards will ... the 2016 National Education Policy Center Bunkum Award. We invite you to enjoy our ... This year’s Bunkum winner is the Center for American Progress (CAP), for its report, ...
(Date:2/23/2017)... , ... February 23, 2017 , ... Hamlin Dental Group ... that they are sponsoring a raffle. Throughout the month of February, patients who visit ... a gift card for a dinner for two at the Cheesecake Factory. , ...
(Date:2/23/2017)... ... February 23, 2017 , ... Pink Pig Publishing ... generations converge and explore the world from different perspectives. By providing a place ... to gain understanding, increase empathy, and find greater happiness. , "Our approach ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... NEW YORK , Feb. 23, 2017  Genesis ... HME Company. The announcement was made by Bill ... David Hartley and Nathan Feltman , ... of Genesis Healthcare Services, LLC. This ... nation,s largest provider of technology enabled durable medical equipment ...
(Date:2/23/2017)... -- Cogentix Medical, Inc. (NASDAQ: CGNT), a medical device company ... the urology market, will release financial results for the ... before the market open on Thursday, March 9, 2017. ... call and webcast to discuss its financial results the ... a.m. Eastern Time (10:00 a.m. Central Time). Darin ...
(Date:2/23/2017)... REDWOOD CITY, Calif., Feb. 23, 2017 Nevro Corp. ... innovative evidence-based solutions for the treatment of chronic pain, today ... ended December 31, 2016. 2016 Accomplishment & ... the full year 2016, an increase of 228% as reported, ... million for 2016, an increase of 612% over the prior ...
Breaking Medicine Technology: